Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global point-of-care infectious disease diagnostics market was valued at USD 5.34 billion in 2023 and is projected to reach USD 8.91 billion by 2030, exhibiting a CAGR of 7.6% during the forecast period.
Point-of-care (POC) infectious disease diagnostics are rapid testing devices that enable near-patient detection of pathogens without requiring specialized laboratory equipment. These portable systems identify various infections including HIV, hepatitis, influenza, tuberculosis, and sexually transmitted diseases through technologies like lateral flow assays, molecular diagnostics, and microfluidics. The market encompasses standalone devices, over-the-counter test kits, and reader-based systems delivering results within minutes to hours.
This market is witnessing accelerated growth due to rising infectious disease prevalence, with WHO reporting 17% of global deaths annually from communicable diseases. The COVID-19 pandemic substantially boosted demand, as POC tests facilitated decentralized testing strategies. Other key drivers include increasing healthcare accessibility needs in developing regions, technological advancements improving test accuracy (such as Abbott's ID NOW platform with 95% sensitivity), and growing adoption in non-traditional settings like pharmacies and workplaces. However, regulatory hurdles and reimbursement challenges in some markets may temporarily restrain growth.
Growing Demand for Rapid Diagnostic Solutions
The increasing prevalence of infectious diseases such as COVID-19, influenza, and STDs is driving the demand for point-of-care diagnostics. Hospitals and clinics are adopting these solutions to enable faster clinical decision-making and reduce time-to-treatment, with average turnaround times improving by over 60% compared to traditional lab tests.
Technological Advancements in Diagnostic Devices
Recent innovations in microfluidics, biosensors, and molecular diagnostics have enhanced the accuracy and portability of point-of-care devices. The global market has seen a 35% increase in FDA/CE-approved rapid tests since 2020, particularly for respiratory and tropical diseases.
Point-of-care diagnostics reduce hospital stays by 2-3 days on average for infectious disease cases, creating significant cost savings for healthcare systems
Decentralization of healthcare services and the need for testing in resource-limited settings further bolster market growth, with emerging economies showing 18-22% annual growth in POC adoption rates.
MARKET CHALLENGES
Regulatory Hurdles and Quality Concerns
Stringent regulatory requirements for diagnostic test approval create significant barriers to market entry. Approximately 30% of proposed POC tests fail to meet sensitivity/specificity thresholds during clinical validation phases, particularly for multiplex assays.
Other Challenges
Skilled Personnel Shortage
Implementation of complex POC devices requires trained operators, with surveys indicating 42% of rural clinics lack staff with adequate molecular diagnostic training.
High Development Costs and Reimbursement Limitations
The average R&D cost for a new POC infectious disease test exceeds $15 million, while reimbursement policies in many markets don't fully cover rapid diagnostic procedures. This creates financial barriers for both developers and end-users, particularly in outpatient settings.
Expansion in Emerging Markets and Home Testing
Developing regions with high infectious disease burdens represent significant growth potential, with the Asia-Pacific POC diagnostics market projected to grow at 14.7% CAGR through 2028. Direct-to-consumer testing models for conditions like HIV and hepatitis are gaining traction, with home test kit sales increasing by 28% annually in key markets.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
HIV POC diagnostics represent the most critical segment due to the global prevalence of HIV/AIDS and the need for rapid testing in resource-limited settings. Influenza POC tests are experiencing growing demand due to seasonal outbreaks and pandemic preparedness. Respiratory virus diagnostics are gaining traction with increased focus on respiratory health post-COVID-19. |
| By Application |
|
Hospitals maintain dominance as primary users due to high patient volumes and need for immediate diagnostics. Home testing shows the strongest growth potential with increasing consumer demand for self-testing options post-pandemic. Clinics benefit from rapid results for immediate treatment decisions, while assisted living facilities increasingly adopt POC tests for infection control. |
| By End User |
|
Healthcare Professionals remain the primary end users, relying on POC diagnostics for clinical decision-making. The Individuals/Patients segment is expanding most rapidly with growing health awareness and availability of OTC test kits. Public health agencies increasingly deploy POC tests for epidemiological surveillance and outbreak management. |
| By Technology |
|
Lateral Flow Assays dominate due to their simplicity and low cost, particularly in low-resource settings. Molecular diagnostics are gaining share with their superior accuracy, especially for complex infections like TB. Immunoassays maintain strong position for antibody detection with ongoing improvements in sensitivity and specificity. |
| By Disease Severity |
|
Acute Infections testing represents the largest segment, driven by urgent need for rapid diagnosis in conditions like sepsis or pneumonia. Chronic infection monitoring is growing steadily with long-term disease management needs. Opportunistic infection diagnostics are gaining importance in immunocompromised patient populations with specialized testing requirements. |
Innovation and Strategic Partnerships Drive Market Leadership
The point-of-care infectious disease diagnostics market is highly competitive with Thermo Fisher Scientific and Abbott leading through continuous R&D investments and expansive product portfolios. These dominant players leverage their global distribution networks and strategic acquisitions to maintain market share. The industry structure shows increasing consolidation as larger firms acquire promising startups with novel diagnostic technologies.
Specialized players like Quidel and Sekisui Diagnostics compete through niche innovations in rapid testing kits. Emerging companies focus on portable molecular diagnostic solutions and multiplex assay platforms. The COVID-19 pandemic accelerated growth for manufacturers with FDA/CE-approved POC tests, creating new opportunities for market entrants.
List of Key Point-of-Care Infectious Disease Diagnostics Companies ProfiledThermo Fisher Scientific
Quidel Corporation
Sekisui Diagnostics
Meridian Bioscience
OraSure Technologies
Trinity Biotech
MedMira Inc.
Bio-Rad Laboratories
Calypte Biomedical
Danaher Corporation
Siemens Healthineers
The global Point-of-care Infectious Disease Diagnostics market was valued at $XX million in 2024 and is projected to reach US$ XX million by 2031, growing at a CAGR of X% during the forecast period. This growth is primarily driven by technological innovations that enable faster, more accurate testing outside traditional lab settings.
Other TrendsExpanding Test Menu for Diverse Pathogens
The market shows increasing segmentation with specialized tests for HIV, Hepatitis B/C, respiratory viruses (RSV, Influenza), and resistant pathogens like MRSA and TB. HIV POC testing currently dominates with XX% market share, while Influenza/Flu POC tests are seeing fastest growth due to seasonal demand patterns.
Shift Toward Decentralized Testing ModelsHospitals currently account for XX% of POC diagnostic usage, but clinics and home settings are growing at X% CAGR. The COVID-19 pandemic accelerated adoption in non-traditional settings, with manufacturers developing simpler devices for use in pharmacies and assisted living facilities.
Regional Market Dynamics
North America leads with XX% market share due to established healthcare infrastructure, while Asia-Pacific shows highest growth (X% CAGR) driven by increasing healthcare access in China and India. Emerging markets are adopting lower-cost POC solutions for tuberculosis and hepatitis screening programs.
Competitive Landscape and Future OutlookThe market remains concentrated with top 5 players (Abbott, Quidel, Thermo Fisher, etc.) holding XX% share. Key developments include multiplex testing platforms and connectivity solutions integrating results with electronic health records. Regulatory harmonization and reimbursement policies will significantly influence future market expansion.
Regional Analysis: Point-of-care Infectious Disease Diagnostics MarketEurope
Europe represents the second-largest market for point-of-care infectious disease diagnostics, with strong growth in decentralized testing models. The EU's IVDR regulations are reshaping market access, favoring high-quality quantitative tests over traditional qualitative assays. Germany and France lead in hospital-based POC adoption, particularly for sepsis and respiratory infections. The UK's NHS is expanding community diagnostic centers equipped with rapid testing capabilities. Eastern European markets show increasing demand for affordable TB and HIV rapid tests in primary care settings.
Asia-Pacific
The Asia-Pacific region is witnessing the fastest growth in POC infectious disease diagnostics, driven by improving healthcare access and rising infectious disease burdens. China dominates the regional market with its rapidly expanding primary care infrastructure and growing middle-class demand for convenient testing. India sees strong uptake in rural health missions using malaria and dengue rapid tests. Southeast Asian countries are investing in POC platforms for emerging infectious disease surveillance following COVID-19 experience.
Latin America
Latin America shows moderate but steady growth in POC infectious disease diagnostics, with Brazil and Mexico leading adoption. The region's high burden of dengue, Zika, and chikungunya drives demand for arbovirus rapid tests. Universal healthcare systems in several countries incorporate POC testing into primary care expansion programs. Challenges remain in cold chain logistics for test distribution in tropical climates and remote Amazonian regions.
Middle East & Africa
The Middle East & Africa market is bifurcated between Gulf states with advanced hospital POC capabilities and Sub-Saharan Africa reliant on donor-funded rapid tests. South Africa leads in HIV and TB POC adoption, while North African countries focus on hepatitis C elimination programs. Middle Eastern markets show particular strength in hospital-based syndromic panels for critical care infections.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global point-of-care infectious disease diagnostics market was valued at USD 5.34 billion in 2023 and is projected to reach USD 8.91 billion by 2030, exhibiting a CAGR of 7.6% during the forecast period.
Which key companies operate in Global Point-of-care Infectious Disease Diagnostics Market?
-> Key players include Thermo Fisher Scientific, Abbott, Quidel, OraSure Technologies, and Meridian Bioscience, among others.
-> Key growth drivers include rising infectious disease prevalence, increasing healthcare accessibility needs, and technological advancements improving test accuracy.
-> North America is the dominant market, while Asia-Pacific is the fastest-growing region.
-> Emerging trends include decentralized testing strategies, adoption in non-traditional settings, and development of rapid molecular diagnostics.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates